ZBTB7B Antibody

What is ZBTB7B and why is it significant in immunological research?

ZBTB7B, also known as Zinc finger protein Th-POK or Zfp-67, is a 539 amino acid nuclear transcription factor that functions as a key regulator of lineage commitment in immature T-cell precursors. Its significance stems from its crucial role in CD4+ vs CD8+ T-cell lineage determination, where it is necessary and sufficient for CD4 lineage commitment, while its absence results in CD8 commitment .

In research applications, ZBTB7B has gained prominence because:

• It regulates CD4+ vs CD8+ T-cell lineage commitment primarily by repressing RUNX3

• It maintains the integrity and function of mature CD4+ T cells

• It influences the development of unconventional T cells including γδ+ and iNKT cells

• Recent studies have implicated it in cancer immune evasion mechanisms

How does ZBTB7B molecular weight appear in experimental applications?

While the calculated molecular weight of ZBTB7B is approximately 58 kDa (based on its 539 amino acid sequence), researchers should note that the observed molecular weight in Western blot applications is typically around 70 kDa due to post-translational modifications . This discrepancy is important to consider when planning experiments, particularly for protein detection and validation.

What applications are ZBTB7B antibodies validated for in research?

Based on current research applications, ZBTB7B antibodies have been validated for multiple experimental techniques:

For optimal results, researchers should titrate antibodies in each testing system, as reactivity can be sample-dependent .

What is the recommended sample preparation protocol for Western blot detection of ZBTB7B?

When preparing samples for Western blot detection of ZBTB7B:

• Lyse cells in appropriate buffer containing protease inhibitors

• Quantify protein concentration using Bradford or BCA assay

• Load 20-40 μg of total protein per lane

• Run samples on 8-10% SDS-PAGE gels (optimal for 70 kDa protein)

• Transfer to PVDF or nitrocellulose membrane

• Block with 5% non-fat milk or BSA in TBST

• Incubate with ZBTB7B antibody at recommended dilution (typically 1:500-1:2000)

• Validate specificity using positive controls such as HepG2 or HeLa cell lysates, which show detectable ZBTB7B expression

Note that storage conditions for ZBTB7B antibodies typically recommend -20°C with 0.02% sodium azide and 50% glycerol (pH 7.3) for maintenance of activity, with stability for one year after shipment .

How can researchers validate ZBTB7B antibody specificity for their experimental system?

Proper validation of ZBTB7B antibodies involves multiple approaches:

• Positive and negative controls:

  • Use HepG2 or HeLa cells as positive controls for human ZBTB7B

  • Compare with ZBTB7B knockout cell lines generated through CRISPR-Cas9

• Peptide competition assay:

  • Pre-incubate antibody with immunizing peptide

  • Run parallel Western blots with competed and non-competed antibody

  • Signal should be significantly reduced in competed samples

• Cross-validation with multiple antibodies:

  • Test multiple ZBTB7B antibodies against different epitopes (N-terminal, middle region, C-terminal)

  • Compare staining patterns across antibodies

• RNA knockdown correlation:

  • Correlate antibody signal reduction with siRNA or shRNA knockdown of ZBTB7B mRNA levels

  • Quantify both protein and mRNA reduction

• Reactivity testing:

  • Confirm species reactivity matches your experimental system

  • Available antibodies show reactivity with human and mouse samples, with some also validated for rat, cow, dog, guinea pig, horse, and rabbit samples

What are the critical considerations for using ZBTB7B antibodies in ChIP experiments?

When designing ChIP experiments to study ZBTB7B binding to DNA:

• Chromatin preparation:

  • Cross-link protein-DNA complexes with formaldehyde (typically 1%)

  • Sonicate to produce DNA fragments of 200-1000 base pairs

  • Optimize sonication conditions for your cell type

• Antibody selection:

  • Choose antibodies validated for ChIP applications

  • Include IgG antibody as negative control

  • Consider using multiple antibodies against different epitopes

• Immunoprecipitation:

  • Adjust concentration appropriately

  • Incubate with ZBTB7B antibody and IgG control

  • Include input control (non-immunoprecipitated chromatin)

• DNA purification and analysis:

  • After elution from the complex, purify DNA fragments

  • Analyze target DNA fragments by qPCR using primers specific for predicted ZBTB7B binding regions

  • Consider using promoter regions of known ZBTB7B targets, such as LDHA, based on research showing ZBTB7B binds to LDHA promoter regions

• Data interpretation:

  • Calculate enrichment relative to input and IgG control

  • Validate findings with reporter gene assays for functional confirmation

How can ZBTB7B antibodies be used to study T-cell differentiation mechanisms?

ZBTB7B plays a critical role in T-cell differentiation, making its study particularly relevant for immunological research:

• Flow cytometry applications:

  • Use ZBTB7B antibodies in combination with surface markers (CD4, CD8, CD24, etc.)

  • Analyze expression in different T-cell subsets

  • Correlate ZBTB7B expression with lineage commitment markers

• Functional studies:

  • Analyze ZBTB7B expression in thymic development stages

  • Study interaction with RUNX3, which ZBTB7B represses to promote CD4+ T-cell development

  • Investigate how ZBTB7B prevents transdifferentiation of CD4+ T cells into CD4-CD8+ T cells

• Co-immunoprecipitation:

  • Identify ZBTB7B interaction partners involved in CD4/CD8 lineage commitment

  • Study interactions with other transcription factors like GATA3, which acts upstream of ZBTB7B

• ChIP-seq applications:

  • Map ZBTB7B binding sites genome-wide

  • Identify target genes regulated by ZBTB7B during T-cell differentiation

  • Compare binding patterns in different T-cell subsets

• T-cell co-culture models:

  • Use CD8+ T cells sorted from spleens with flow cytometry

  • Study effects of ZBTB7B modulation on T-cell interactions with other cell types

What approaches can be used to study ZBTB7B's role in cancer biology using antibodies?

Recent research has implicated ZBTB7B in cancer processes, particularly in immune evasion mechanisms:

• Super-enhancer profiling:

  • Utilize ChIP-seq with H3K27ac antibodies to identify super-enhancers associated with ZBTB7B

  • Recent studies have shown ZBTB7B is linked to a large ubiquitous super-enhancer, with lower H3K27ac signal near the transcriptional start site in triple-negative breast cancer (TNBC) lines compared to luminal cell lines

• BRD4 inhibition studies:

  • Use BRD4 inhibitors like JQ1 or iBET-151 to disrupt super-enhancer activity

  • Monitor effects on ZBTB7B expression

  • Acute BRD4 inhibition (6h) has been shown to reduce ThPOK (ZBTB7B) expression

• CRISPR-Cas9 knockout models:

  • Generate ZBTB7B knockout cell lines using validated sgRNA designs

  • Validate knockout by Western blot using ZBTB7B antibodies

  • Study phenotypic effects of ZBTB7B loss in cancer models

• ALDH1A1-ZBTB7B axis investigation:

  • Study how ALDH1A1 regulates ZBTB7B in tumor glycolysis

  • Investigate ZBTB7B binding to LDHA promoter regions

  • Analyze effects on immune escape mechanisms in tumors

What are common issues when using ZBTB7B antibodies and how can they be resolved?

How can researchers optimize ZBTB7B SUMOylation studies?

ZBTB7B undergoes SUMOylation, which stabilizes its transcriptional activity . To study this process:

• Co-immunoprecipitation approach:

  • Immunoprecipitate with ZBTB7B antibody

  • Blot with SUMO antibodies to detect SUMOylated ZBTB7B

  • Include controls for non-SUMOylated ZBTB7B

• Site-directed mutagenesis:

  • Identify potential SUMOylation sites using prediction tools

  • Generate ZBTB7B mutants at these sites

  • Use ZBTB7B antibodies to compare stability and function of wild-type vs. mutant proteins

• SUMO inhibitor studies:

  • Treat cells with SUMO inhibitors

  • Monitor effects on ZBTB7B stability and function

  • Use ZBTB7B antibodies to assess protein levels and localization

• Transcriptional activity assays:

  • Use luciferase reporter constructs containing ZBTB7B binding sites

  • Compare activity with and without SUMOylation perturbation

  • Correlate with ZBTB7B protein levels detected by antibodies

What emerging applications of ZBTB7B antibodies show promise for translational research?

Recent findings suggest several promising directions for ZBTB7B research with translational potential:

• Tumor immunotherapy approaches:

  • ZBTB7B has been implicated in tumor immune evasion mechanisms

  • Targeting ALDH1A1 and ZBTB7B in combination with immunotherapy shows potential

  • ZBTB7B antibodies can be valuable tools for monitoring expression in patient samples

• Metabolic disease connections:

  • ZBTB7B is compensatively increased during progression of MASLD (Metabolic dysfunction-Associated Steatotic Liver Disease)

  • It restricts lipid deposition in the liver by regulating H19-mediated de novo lipogenesis

  • Antibodies can help track expression changes in disease progression

• Breast cancer progression markers:

  • Super-enhancer profiling reveals ThPOK/ZBTB7B as a potential suppressor of breast cancer progression

  • Significantly under-active in triple-negative breast cancer and over-active in luminal cell lines

  • Antibodies are essential for validating these findings in patient samples

How might single-cell approaches benefit from ZBTB7B antibody applications?

Emerging single-cell technologies create new opportunities for ZBTB7B research:

• Single-cell protein profiling:

  • Use ZBTB7B antibodies in mass cytometry (CyTOF) to correlate expression with lineage markers

  • Apply in single-cell Western blotting for more nuanced expression analysis

  • Combine with other transcription factor antibodies to build regulatory networks

• Spatial transcriptomics integration:

  • Combine ZBTB7B immunohistochemistry with spatial transcriptomics

  • Correlate protein expression with gene expression patterns in tissue context

  • Map ZBTB7B distribution in relation to T-cell populations in lymphoid tissues

• High-parameter flow cytometry:

  • Include ZBTB7B in multi-parameter flow cytometry panels

  • Correlate with T-cell differentiation markers

  • Analyze heterogeneity in ZBTB7B expression within T-cell populations

• Single-cell ChIP-seq applications:

  • Use ZBTB7B antibodies to map binding sites at single-cell resolution

  • Identify cell-specific regulatory mechanisms

  • Correlate with single-cell transcriptomics data